Cell or Molecular Dysfunction

GSK walks away from remaining IDEAYA programs, formally ending partnership

1 day ago talkbio0Tagged Collaboration termination, DNA Repair, drug development pipeline, Ideaya Biosciences, License Agreement, oncology partnership, Pol Theta, SmithKline Beecham, Synthetic Lethality, Werner helicase

GSK; IDEAYA Biosciences; synthetic lethality; collaboration termination; Werner helicase; Pol Theta; DNA damage repair; oncology partnership; license agreement; drug development pipeline

UniQure restates FDA’s negative feedback on Huntington’s trial; Neurimmune expands AstraZeneca alliance

5 days ago talkbio0Tagged AMT-130, antibody collaboration, AstraZeneca, biopharmaceutical partnerships, external control group, Feedback - system communication, gene therapy, Nerve Degeneration, Neurimmune, UniQure, United States Food and Drug Administration

UniQure; AMT-130; FDA feedback; external control group; gene therapy; Neurimmune; AstraZeneca; neurodegeneration; antibody collaboration; licensing deal; biopharmaceutical partnerships

Marengo’s invikafusp alfa shows promising monotherapy activity in PD-1 resistant gastrointestinal cancers

1 week ago talkbio0Tagged Alfa, Colorectal Carcinoma, fast-track designation, High tumor mutational burden, High-Frequency Microsatellite Instability, Immunotherapy, invikafusp, Malignant neoplasm of gastrointestinal tract, Marengo Therapeutics, PDCD1 gene, resistant tumors, United States Food and Drug Administration

Invikafusp alfa; Marengo Therapeutics; PD-1 resistant tumors; Gastrointestinal cancers; Colorectal cancer; TMB-H; MSI-H; Immunotherapy; ESMO 2025; FDA Fast Track designation

FDA Approves Syndax’s First-in-Class Menin Inhibitor with Black-Box Warning; Updates on GSK’s ADC Deal

1 month ago talkbio0Tagged Acute leukemia, Antibody-Drug Conjugates, Approved, black-box warning, Chromosomal translocation, differentiation syndrome, KMT2A gene, Leukemia, Myelocytic, Acute, Menin Inhibitor, oncology drug approval, Revuforj, revumenib, SmithKline Beecham, Syndax, United States Food and Drug Administration

Syndax; Revuforj; revumenib; FDA approval; menin inhibitor; black-box warning; acute leukemia; KMT2A translocation; differentiation syndrome; acute myeloid leukemia (AML); GSK; antibody-drug conjugate (ADC); oncology drug approval

Accuray Accelerates Transformation Efforts with Appointments of Experienced Executive Leaders

2 months ago talkbio0Tagged Accuray, cell transformation, CEO, Change, Organizational, executive appointments, Leadership, med-tech, operational transformation, Steve La Neve, Suzanne Winter, Transition Mutation

Accuray; transformation; executive appointments; Steve La Neve; CEO; Suzanne Winter; organizational change; operational transformation; med-tech; leadership transition

GSK CEO Emma Walmsley Steps Down After 9 Years; Luke Miels to Succeed

2 months ago talkbio0Tagged CEO, Drug Industry, Emma Walmsley, Haleon demerger, Leadership Change, Luke Miels, SmithKline Beecham, specialty medicines, Succession planning, Transition Mutation, Vaccines

Emma Walmsley; GSK; CEO transition; Luke Miels; leadership change; pharmaceutical industry; Haleon demerger; specialty medicines; vaccines; succession planning

uniQure’s Gene Therapy AMT-130 Significantly Slows Huntington’s Progression in Pivotal Trial

3 months ago talkbio0Tagged AMT-130, Approved, Clinical Trials, Disease Progression, gene therapy, huntingtin-lowering, Huntington 's disease, Nerve Degeneration, UniQure, United States Food and Drug Administration

Gene therapy; uniQure; AMT-130; Huntington’s disease; clinical trial; disease progression; FDA approval; huntingtin-lowering; neurodegeneration

Novartis Takes Another Shot at Alpha-Synuclein With $2.2B Arrowhead CNS Deal

3 months ago talkbio0Tagged alpha-Synuclein, ARO-SNCA, Arrowhead Pharmaceuticals, biotech partnerships, Gene Silencing, Nerve Degeneration, Novartis, Parkinson 's disease, RNA Interference, TRiM platform

Novartis; Arrowhead Pharmaceuticals; alpha-synuclein; Parkinson’s disease; RNA interference (RNAi); gene silencing; ARO-SNCA; TRiM platform; neurodegeneration; biotech partnerships